Study of the atopic march: Development of atopic comorbidities

Lynda Schneider, Jon Hanifin, Mark Boguniewicz, Lawrence F. Eichenfield, Jonathan M. Spergel, Rada Dakovic, Amy S. Paller

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Background: Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety. Methods: This was a 3-year double-blind study in which patients were randomized to pimecrolimus or vehicle and then open-label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease-free days, Eczema Area and Severity Index, and body surface area affected. Results: Infants ages 3 to 18 months with recent-onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus- and placebo-treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar. Conclusions: This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.

Original languageEnglish (US)
Pages (from-to)388-398
Number of pages11
JournalPediatric Dermatology
Volume33
Issue number4
DOIs
StatePublished - Jul 1 2016

Fingerprint

Atopic Dermatitis
Comorbidity
Allergic Conjunctivitis
Asthma
Food Hypersensitivity
Body Surface Area
Eczema
Double-Blind Method
Caregivers
pimecrolimus
Adrenal Cortex Hormones
Placebos
Research Personnel
Observation
Safety
Incidence
Allergic Rhinitis

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Schneider, L., Hanifin, J., Boguniewicz, M., Eichenfield, L. F., Spergel, J. M., Dakovic, R., & Paller, A. S. (2016). Study of the atopic march: Development of atopic comorbidities. Pediatric Dermatology, 33(4), 388-398. https://doi.org/10.1111/pde.12867

Study of the atopic march : Development of atopic comorbidities. / Schneider, Lynda; Hanifin, Jon; Boguniewicz, Mark; Eichenfield, Lawrence F.; Spergel, Jonathan M.; Dakovic, Rada; Paller, Amy S.

In: Pediatric Dermatology, Vol. 33, No. 4, 01.07.2016, p. 388-398.

Research output: Contribution to journalArticle

Schneider, L, Hanifin, J, Boguniewicz, M, Eichenfield, LF, Spergel, JM, Dakovic, R & Paller, AS 2016, 'Study of the atopic march: Development of atopic comorbidities', Pediatric Dermatology, vol. 33, no. 4, pp. 388-398. https://doi.org/10.1111/pde.12867
Schneider L, Hanifin J, Boguniewicz M, Eichenfield LF, Spergel JM, Dakovic R et al. Study of the atopic march: Development of atopic comorbidities. Pediatric Dermatology. 2016 Jul 1;33(4):388-398. https://doi.org/10.1111/pde.12867
Schneider, Lynda ; Hanifin, Jon ; Boguniewicz, Mark ; Eichenfield, Lawrence F. ; Spergel, Jonathan M. ; Dakovic, Rada ; Paller, Amy S. / Study of the atopic march : Development of atopic comorbidities. In: Pediatric Dermatology. 2016 ; Vol. 33, No. 4. pp. 388-398.
@article{517632be6a7048dfb5d01c80d697df9b,
title = "Study of the atopic march: Development of atopic comorbidities",
abstract = "Background: Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety. Methods: This was a 3-year double-blind study in which patients were randomized to pimecrolimus or vehicle and then open-label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease-free days, Eczema Area and Severity Index, and body surface area affected. Results: Infants ages 3 to 18 months with recent-onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus- and placebo-treated groups were found in the percentage of patients with AD who developed asthma (10.7{\%}) or other allergic conditions (allergic rhinitis, 22.4{\%}; food allergy, 15.9{\%}; allergic conjunctivitis, 14.1{\%}; one or more atopic comorbidities, 37.0{\%}) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar. Conclusions: This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.",
author = "Lynda Schneider and Jon Hanifin and Mark Boguniewicz and Eichenfield, {Lawrence F.} and Spergel, {Jonathan M.} and Rada Dakovic and Paller, {Amy S.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1111/pde.12867",
language = "English (US)",
volume = "33",
pages = "388--398",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Study of the atopic march

T2 - Development of atopic comorbidities

AU - Schneider, Lynda

AU - Hanifin, Jon

AU - Boguniewicz, Mark

AU - Eichenfield, Lawrence F.

AU - Spergel, Jonathan M.

AU - Dakovic, Rada

AU - Paller, Amy S.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background: Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety. Methods: This was a 3-year double-blind study in which patients were randomized to pimecrolimus or vehicle and then open-label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease-free days, Eczema Area and Severity Index, and body surface area affected. Results: Infants ages 3 to 18 months with recent-onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus- and placebo-treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar. Conclusions: This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.

AB - Background: Atopic dermatitis (AD) is often the first step in the atopic march leading to the development of asthma or allergic rhinitis. The goal of this study was to determine whether early intervention with pimecrolimus limits the atopic march in infants with AD and to evaluate its efficacy and safety. Methods: This was a 3-year double-blind study in which patients were randomized to pimecrolimus or vehicle and then open-label pimecrolimus for a planned further 3 years. Rescue topical corticosteroid was permitted if 3 days of study medication led to no improvement; investigators made decisions on rescue medication until week 14 and caregivers thereafter. Efficacy assessments included disease-free days, Eczema Area and Severity Index, and body surface area affected. Results: Infants ages 3 to 18 months with recent-onset AD (≤3 months) were observed for a mean of 2.8 years (N = 1,091). No significant differences between pimecrolimus- and placebo-treated groups were found in the percentage of patients with AD who developed asthma (10.7%) or other allergic conditions (allergic rhinitis, 22.4%; food allergy, 15.9%; allergic conjunctivitis, 14.1%; one or more atopic comorbidities, 37.0%) by study end. Allergic rhinitis, food allergy, and having one or more atopic comorbidities (but not asthma or allergic conjunctivitis alone) developed significantly more often in infants with greater AD severity at baseline. Pimecrolimus was significantly more effective than vehicle for AD treatment at week 14. Adverse event incidences were similar. Conclusions: This longitudinal observation of infants with AD provides evidence of the atopic march. Pimecrolimus was safe and effective in infants with mild to moderate AD.

UR - http://www.scopus.com/inward/record.url?scp=84978096877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978096877&partnerID=8YFLogxK

U2 - 10.1111/pde.12867

DO - 10.1111/pde.12867

M3 - Article

C2 - 27273433

AN - SCOPUS:84978096877

VL - 33

SP - 388

EP - 398

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 4

ER -